VALIANT and EUROPA.
Liebson
Philip R
PR
Section of Cardiology, Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA. pliebson@rush.edu
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003327:Coronary Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D006333:Heart Failure / Q000150:complications; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D020913:Perindopril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000068756:Valsartan; D018487:Ventricular Dysfunction, Left / Q000150:complications
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D013777:Tetrazoles; D000068756:Valsartan; D002216:Captopril; D014633:Valine; D020913:Perindopril